KR101856210B1 - 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체 - Google Patents

활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체 Download PDF

Info

Publication number
KR101856210B1
KR101856210B1 KR1020107011548A KR20107011548A KR101856210B1 KR 101856210 B1 KR101856210 B1 KR 101856210B1 KR 1020107011548 A KR1020107011548 A KR 1020107011548A KR 20107011548 A KR20107011548 A KR 20107011548A KR 101856210 B1 KR101856210 B1 KR 101856210B1
Authority
KR
South Korea
Prior art keywords
antibody
apc
protein
delete delete
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107011548A
Other languages
English (en)
Korean (ko)
Other versions
KR20100116166A (ko
Inventor
쥔 쉬
찰스 에스몬
Original Assignee
오클라호마 메디컬 리써치 화운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오클라호마 메디컬 리써치 화운데이션 filed Critical 오클라호마 메디컬 리써치 화운데이션
Publication of KR20100116166A publication Critical patent/KR20100116166A/ko
Application granted granted Critical
Publication of KR101856210B1 publication Critical patent/KR101856210B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020107011548A 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체 Active KR101856210B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
US60/983,092 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157020430A Division KR20150092358A (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체

Publications (2)

Publication Number Publication Date
KR20100116166A KR20100116166A (ko) 2010-10-29
KR101856210B1 true KR101856210B1 (ko) 2018-05-09

Family

ID=40289112

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107011548A Active KR101856210B1 (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체
KR1020157020430A Ceased KR20150092358A (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157020430A Ceased KR20150092358A (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체

Country Status (13)

Country Link
US (3) US8153766B2 (enExample)
EP (1) EP2205638B1 (enExample)
JP (3) JP2011500843A (enExample)
KR (2) KR101856210B1 (enExample)
CN (3) CN103232541A (enExample)
AU (1) AU2008316661B2 (enExample)
BR (1) BRPI0818865A2 (enExample)
CA (1) CA2703738C (enExample)
IL (2) IL205284A (enExample)
MX (1) MX2010004615A (enExample)
RU (2) RU2539729C2 (enExample)
WO (1) WO2009055669A2 (enExample)
ZA (1) ZA201105704B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ730271A (en) * 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
CN104812402A (zh) * 2012-11-29 2015-07-29 拜尔健康护理有限责任公司 针对活化蛋白C (aPC)的单克隆抗体
HK1215174A1 (zh) * 2012-11-29 2016-08-19 Bayer Healthcare Llc 針對活化蛋白c的人源化單克隆抗體及其用途
EP3047857A4 (en) * 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CA3067584A1 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
TW201906868A (zh) * 2017-07-07 2019-02-16 日商第一三共股份有限公司 抗蛋白ｃ抗體
EP3655437A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Human antibodies binding to ror2
EP3971573A1 (en) * 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
US12319744B2 (en) 2018-09-06 2025-06-03 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
AU2019360758B2 (en) * 2018-10-18 2024-08-08 Oklahoma Medical Research Foundation Biomarkers for a Systemic Lupus Erythematosus (SLE) disease activity immune index that characterizes disease activity
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bayl Univ Med. Cent. Proc., Vol. 15, No. 2, pp. 224-227 (2002.04.)*
J. Biol. Chem., Vol. 267, No. 36, pp. 26104-26109 (1992.12.25.)*
J. Thromb. Haemost., Vol. 1, No. 4, pp. 662-670 (2003.04.)*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Also Published As

Publication number Publication date
JP2014237651A (ja) 2014-12-18
CN103232541A (zh) 2013-08-07
US20120164150A1 (en) 2012-06-28
IL220622A0 (en) 2012-08-30
MX2010004615A (es) 2010-07-06
US20090110683A1 (en) 2009-04-30
RU2012150953A (ru) 2014-06-10
EP2205638B1 (en) 2017-03-01
AU2008316661B2 (en) 2013-05-23
CN101918453A (zh) 2010-12-15
RU2539729C2 (ru) 2015-01-27
IL205284A (en) 2014-06-30
WO2009055669A2 (en) 2009-04-30
EP2205638A2 (en) 2010-07-14
US8153766B2 (en) 2012-04-10
JP6117741B2 (ja) 2017-04-19
KR20150092358A (ko) 2015-08-12
JP2013049694A (ja) 2013-03-14
AU2008316661A1 (en) 2009-04-30
RU2010121148A (ru) 2011-12-10
BRPI0818865A2 (pt) 2015-05-05
IL205284A0 (en) 2010-12-30
CN105153308A (zh) 2015-12-16
US20150344588A1 (en) 2015-12-03
US9127072B2 (en) 2015-09-08
CA2703738A1 (en) 2009-04-30
CA2703738C (en) 2018-02-27
KR20100116166A (ko) 2010-10-29
JP2011500843A (ja) 2011-01-06
ZA201105704B (en) 2014-05-28
WO2009055669A3 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
KR101856210B1 (ko) 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체
US12049505B2 (en) Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
CN106163556B (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
US20220233705A1 (en) Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
AU2022241636B2 (en) Method of treating atherosclerosis
US12357691B2 (en) Antibodies specifically binding to CD147 and uses thereof
WO2015158851A1 (en) Antibodies for the prevention or the treatment of bleeding episodes
US9463217B1 (en) Methods and pharmaceutical compositions for treatment of retinal occlusion
AU2016203760B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2015200348B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2013202464B2 (en) Monoclonal antibodies against activated and unactivated protein c
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c
WO2021136639A1 (en) Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100526

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131018

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150327

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150727

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151223

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150327

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20160122

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20151223

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101000382

Request date: 20160122

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20160122

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20160122

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20150727

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20131018

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160316

Patent event code: PE09021S01D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20160923

J301 Trial decision

Free format text: TRIAL NUMBER: 2016101000382; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160122

Effective date: 20180131

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20180131

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20160122

Decision date: 20180131

Appeal identifier: 2016101000382

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20180222

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20180201

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180502

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180502

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 4

End annual number: 4